Publications by authors named "Grece Saba"
Article Synopsis
- - The study investigates the impact of impaired vitality on the general healthy population in Europe, as highlighted by the World Health Organization’s broader definition of health, which includes both mental and physical wellbeing.
- - Researchers analyzed data from nearly 24,300 healthy participants aged 18-65 across five EU countries, identifying factors like gender, age, obesity, and mental disorders that increase the risk of low vitality, which in turn affects healthcare resource usage and patient-provider engagement.
- - Results indicate that individuals with low vitality experience significantly higher odds of mobility issues, daily activity impairment, and increased pain, as well as greater risks of work-related productivity loss.
Purpose: To provide EuroQoL EQ-5D-5L French population norms based on a sample of 15,000 responders.
Methods: Based on the National Health and Wellness Survey, an international, annual, selfadministered Internet-based survey, this study extracted data from France for 2018 involving a sample of 15,000 respondents stratified by age and gender. Responses to the EQ-5D-5L questionnaire and the Visual Analog Scale (VAS) score, together with sociodemographic, health behavior, and disease status variables were collected.
Background: Little is known on the current global prevalence of atopic dermatitis (AD) in the pediatric population.
Objective: To estimate the real-world global prevalence of AD in the pediatric population and by disease severity.
Methods: This international, cross-sectional, web-based survey of children and adolescents (6 months to <18 years old) was conducted in the following 18 countries: North America (Canada, United States), Latin America (Argentina, Brazil, Columbia, Mexico), Europe (France, Germany, Italy, Spain, United Kingdom), Middle East and Eurasia (Israel, Saudi Arabia, Turkey, United Arab Emirates, Russia), and East Asia (Japan, Taiwan).
Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany.
Clin Lymphoma Myeloma Leuk
February 2021
Introduction: Real-world health-related quality of life (HRQoL) data in patients with multiple myeloma (MM) are scarce. Here, we report HRQoL by line of therapy in adults with MM in clinical practice in Germany.
Patients And Methods: This descriptive, multicenter, observational study included patients receiving all lines of MM therapy or best supportive care (BSC).
The authors would like to correct the images in figures which are in wrong order and require swapping.
View Article and Find Full Text PDFIntroduction: Atopic dermatitis (AD) is an incurable, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Although AD is considered a childhood disease, adult onset is possible, presenting with daily sleep disturbance and functional impairment associated with itch, neuropsychiatric issues (anxiety and depression), and reduced health-related quality of life. Although such aspects of adult AD disease burden have been measured through standardized assessments and based on population-level data, the understanding of the disease experienced at the patient level remains poor.
View Article and Find Full Text PDFIntroduction: New therapies for multiple myeloma (MM) have improved life expectancy, but health-related quality of life (HRQoL) data from patients with MM in the real-world setting are lacking. This study, conducted in France, explored the associations between treatment outcomes and HRQoL in patients with MM.
Patients And Methods: This observational, cross-sectional, multicenter study enrolled patients (≥ 18 years old) with symptomatic MM who had consulted a physician at least once between February and March 2016.
Background: Community Acquired Pneumococcal Pneumonia is a lung infection that causes serious health problems and can lead to complications and death. The aim of this study was to observe and analyze health related quality of life after a hospital episode for patients with community acquired pneumococcal pneumonia in France.
Methods: A total of 524 individuals were enrolled prospectively in the study and were followed for 12 months after hospital discharge.
Objectives: Pneumocost is a prospective study that aimed at documenting the costs of the management of patients hospitalized with a pneumococcal pneumonia and the post-discharge costs during a 6-month period in the French context.
Methods: Billing data were used to document hospital costs. Resource use during the follow-up period was collected through phone interviews at month 1, 3 and 6.
Objectives: Within Europe, contrasting approaches have emerged for rewarding the value added by new drugs. In Ireland, The Netherlands, Sweden and the UK, the price of, and access to, a new drug has to be justified by the health gain it delivers compared with current therapy, typically expressed in quality-adjusted life-years (QALYs) gained. By contrast, in France and Germany, the assessment of added benefit is expressed on an ordinal scale, based on an assessment of the clinical outcomes as compared with existing care.
View Article and Find Full Text PDF